The drug Saikosaponin D encapsulated in SCMNP could inhibit tumor neovascularization by regulating angiogenic pathway related factors such as vascular endothelial growth factor (VEGF), Phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT), and extracellular-regulated kinase (ERK), thus effectively inhibiting tumor growth and metastasis of breast cancer. This evidence concerns the gene AKT1 and breast carcinoma.